News BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Market Closed - Toronto S.E. Other stock markets 03:25:22 2024-04-19 pm EDT			5-day change	1st Jan Change
2.86 ^CAD	-3.05%		-11.73%	-63.33%

Apr. 10	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	CI
Apr. 09	BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	Apr. 10	AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	Apr. 10	CI
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	Apr. 09	MT
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR	Apr. 09	AQ
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K	Apr. 02	PU
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 18	CI
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies	Mar. 07	AQ
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference	Mar. 06	MT
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference	Mar. 06	AQ
BriaCell Provides Update on Alleged Illegal Trading of Public Securities	Feb. 27	AQ
BriaCell Announces Strong Clinical Data in Breast Cancer Patients	Feb. 07	MT
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	Feb. 07	CI
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	Feb. 07	AQ
Toronto Stocks Rally; Precision Drilling Rises on 4Q Profit Growth	Feb. 06	DJ
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing	Feb. 06	AQ
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	Feb. 06	CI
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting	Jan. 30	AQ
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer	Jan. 04	MT
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer	Jan. 04	AQ
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Summary

Filters